secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2024-08-23T23:59:59+00:00
Accession:  0001493152-24-033718
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharma reports 100% pain signal reversal with oral Ketamir-2 in rat neuropathic pain model
--------------------------------------------------------------------------------

- Low oral doses of Ketamir-2 reversed neuropathic pain for 14-22 days in nerve-ligation rat model.
- Highest dose achieved complete normalization of pain threshold, a 100% reversal of pain signal.
- Oral ketamine under same conditions showed no significant pain relief, highlighting Ketamir-2's superiority.
- Company plans further clinical development for Ketamir-2 as a transformative neuropathic pain treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224033718/0001493152-24-033718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224033718/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-033718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer